E.Yu. EREMINA

Mordovia State University named after N.P. Ogarev, 68 Bolshevistskaya St., Saransk, Russian Federation, 430005 

Eremina E.Yu. – D. Med. Sc., Professor, Head of the Chair of Internal Diseases Propedeutics, Chief Gastroenterologist of the Ministry of Health Care of Mordovia Republic, tel. (8342) 47-68-85, e-mail: eeu61@mail.ru

The article is devoted to the up-to-date data of the drug-induced liver diseases problem and series of the clinical monitoring accomplished by the author. It contains the drug-induced liver diseases risk factors, the main mechanisms and the clinical variants of the liver injuries and the main principles of drug-induced liver diseases diagnostics and treatment. The article gives data on the special character of the drug-induced liver injuries during pregnancy: oligosypmtomatic or symptom-free course of disease, prevalence of cytolitic biochemical syndrome and its progression according to the gestational term, lack of strict correlation between intensity of liver function test results and the metabasis, high risk of coagulopathy, necessity for the long-term multiagent monitoring of liver function and hemostasis.

Key words: drug-induced liver diseases, mechanisms, clinical variants, diagnostics principles, treatment.

 

REFERENCES

1. Andrade R., Lucena M., Fernandes M.C. et al. Drug-induced liver injures analisis of 461 residences submitted to the Spanish registry a 10-years period. Gastroenterology, 2005, vol. 129, pp. 512-521.

2. Chang C.Y., Schiano T.D. Review article: drug hepatotoxicity. Alimentary pharmacology & therapeutics, 2007, May 15, vol. 25, no. 10, pp. 1135-1351.

3. Thiim M., Friedman LS. Hepatotoxicity of antibiotics and antifungals. Clin Liver Dis, 2003, May, vol. 7, no. 2, pp. 381-99.

4. Larrey D. Drug-induced liver disease. J. Hepatol, 2000, vol. 32 (suppl. 1), pp. 77-88.

5. Buratti S., Lavine J.E. Drugs and the liver: advances in metabolism, toxicity, and therapeutics. Curr Opin Pediatr, 2002, vol. 14, pp. 601-607.

6. Teschke R., Schmidt-Taenzer W., Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiology and drug safety, 2011, June, vol. 20, no. 6, pp. 567-582.

7. Lewis J.H. Drug-induced liver disease. Med Clin North Am, 2000, vol. 84, pp. 1275-311.

8. Sherlok Sh., Duli Dzh. Zabolevaniya pecheni i zhelchnykh putey [Diseases of the liverand biliary tract]. Moscow, 1999. 864 p.

9. International Consensus Meeting Criteria of drug-induced liver disorders. J. Hepatol, 1990, vol. 11, pp. 272-276.

10. Lucena M.I., Andrade R.J., Martinez C. et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury, Hepatology (Baltimore, Md), 2008, August, vol. 48, no. 2, pp. 588-596.

11. Lucena M.I., Andrade R.J., Kaplowitz N. et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex, Hepatology (Baltimore, Md), 2009, June, vol. 49, no. 6, pp. 2001-2009.

12. Andrade R.J., Lucena M.I., Alonso A. et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology (Baltimore, Md), 2004, June, vol. 39, no. 6, pp. 1603-1612.

13. Day C.P. NASH-related liver failure: one hit too many? The American journal of gastroenterology, 2002, vol. 97, no. 8, pp. 1872-1874.

14. Adukauskiene D., Dockiene I., Naginiene R. et al. Acute liver failure in Lithuania. Medicina (Kaunas, Lithuania), 2008, vol. 44, no. 7, pp. 536-540.

15. Eremina E.Yu., Masharova A.A. Zabolevaniya organov pishchevaritel’noy sistemy u beremennykh [Diseases of the digestive system in pregnant]. Saransk, 2009, 200 p.

16. Marschall H.U., Wagner M., Zollner G., Trauner M. Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. Molecular pharmaceutics, 2007, November-December, vol. 4, no. 6, pp. 895-910.

17. Zimmerman H.J. Drug-induced liver disease. Clin Liver Dis, 2000, February, vol. 4, no. 1, pp. 73-96.

18. Andrade R., Lucena M., Kaplowitz N., Pachkova K. Outcome of acute idiosyncratic drug induced liver injury, J. Hepatol, 2006, vol. 44, pp. 1581-1588.

19. Andrade R.J., Agundez J.A., Lucena M.I. et al. Pharmacogenomics in drug induced liver injury. Curr Drug Metab, 2009, November, vol. 10, no. 9, pp. 956-70.

20. Lucena M.I., Garcia-Martin E., Andrade R.J. et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology (Baltimore, Md), 2010, July, vol. 52, no. 1, pp. 303-312.

21. Bjornsson E., Jerlstad P., Bergqvist A., Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scandinavian journal of gastroenterology, 2005, September, vol. 40, no. 9, pp. 1095-1101.

22. Ostapowicz G., Fontana R.J., Schiodt F.V. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Annals of internal medicine, 2002, December 17, vol. 137, no. 12, pp. 947-954.

23. Wu S.S., Chao C.S., Vargas J.H. et al. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation, 2007, July 27, vol. 84, no. 2, pp. 173-179.

24. Lucena M.I., Kaplowitz N., Hallal H. et al. Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis. Journal of hepatology, 2011, February 19.

25. Liu Z.X., Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis, 2002, vol. 6, pp. 467-86.

26. Farrell G.C. Drugs and steatohepatitis. Semin Liver Dis, 2002, no. 22, pp. 185-94.

27. Kaplowitz N. Drug induced hepatitis. Chronic hepatitis: metabolic, cholestatic, viral and autoimmune. Eds. M. Diel, N. Hayashi, M.P. Manns, T. Samerbruth. Dordrecht. Springer, 2007, pp. 32-42.

28. Khazanov A.I. Ostryy lekarstvennyy gepatit. Gastroenterologiya i gepatologiya: diagnostika i lechenie [Acutedrug-induced hepatitis. Gastroenterology and hepatology: diagnosis and treatment]. Moscow, 2007, pp. 416-420.

29. Andrade R.J., Lucena M.I., Fernandez M.C. et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the panish registry over a 10-year period. Gastroenterology, 2005 August, vol. 129, no. 2, pp. 512-521.

30. Chitturi S., Farrell G.C. Drug-induced cholestasis. Semin Gastrointest Dis, 2001, Vol. 122, pp. 113-24.

31. Aithal G.P., Watkins P.B., Andrade R.J. et al. Case definition and phenotype standardization in drug-induced liver injury. Clinical pharmacology and therapeutics, 2011, June, vol. 89, no. 6, pp. 806-15.

32. Novikov V.E., Klimkina E.I. Farmakologiya gepatoprotektorov. Obzor klinicheskoy farmakologii i lekarstvennoy terapii, 2005, vol. 4, no. 1, pp. 2-20.

33. Morozov S.V., Kucheryavyy Yu.A. Gepatoprotektory v klinicheskoy praktike: ratsional’nye aspekty ispol’zovaniya: posobie dlya vrachey [Hepaticin clinical practice: the rational aspects ofthe use: manual forphysicians]. Moscow, 2011, 28 p.

34. Lieber C.S., Weiss D.G., Groszmann R., Paronetto F., Schenker S. Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease, Alcohol Clin Exp Res., 2003, November, vol. 27, no. 11, pp. 1765-1772.

35. Bjornsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology (Baltimore, Md), 2005, August, vol. 42, no. 2, pp. 481-489